Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
The plans were bounced onto the Chief of Defence Staff, Field Marshal "Dwin" Bramall, over a weekend before publication on Monday, so senior officers had minimal time to drum up opposition in Parliament and the press. There was around three months of protest in the press, including from Bramall's predecessor Admiral of the Fleet Sir Henry Leach. Bramall obtained the concession that the individual service chiefs would be allowed to retain small staffs of their own and have a right of appeal to the prime minister. The changes took effect at the start of 1985. Bramall admired Heseltine's "great drive" and his "style, energy and vision about Europe", but was displeased at Heseltine's rudeness. It was not uncommon for Heseltine to summon him to a meeting early in the day, then keep Bramall "on hold" all day as he kept putting back the meeting, and eventually earning himself a rebuke for failing to display the respect with which every officer in the armed forces is trained to treat his subordinates. A number of senior officers spoke of Heseltine in scathing terms, for example for his self-centredness, to Michael Crick when he was researching his biography. Crick observes that with the exception of some defence chiefs, many people who worked with Heseltine came to "admire and respect him", although those who see him from afar are more suspect.
A protein kinase is a kinase which selectively modifies other proteins by covalently adding phosphates to them (phosphorylation) as opposed to kinases which modify lipids, carbohydrates, or other molecules. Phosphorylation usually results in a functional change of the target protein (substrate) by changing enzyme activity, cellular location, or association with other proteins. The human genome contains about 500 protein kinase genes and they constitute about 2% of all human genes. There are two main types of protein kinase. The great majority are serine/threonine kinases, which phosphorylate the hydroxyl groups of serines and threonines in their targets. Most of the others are tyrosine kinases, although additional types exist. Protein kinases are also found in bacteria and plants. Up to 30% of all human proteins may be modified by kinase activity, and kinases are known to regulate the majority of cellular pathways, especially those involved in signal transduction.
Impatiens balsamina, commonly known as balsam, garden balsam, rose balsam, touch-me-not or spotted snapweed, is a species of plant native to India and Myanmar. It is an annual plant growing to 20–75 cm (7.9–29.5 in) tall, with a thick, but soft stem. The leaves are spirally-arranged, 2.5–9 cm (1.0–3.5 in) long and 1–2.5 cm broad, with a deeply toothed margin. The flowers are pink, red, mauve, purple, lilac, or white, and 2.5–5 cm diameter; they are pollinated by bees and other insects, and also by nectar-feeding birds. The ripe seed capsules undergo explosive dehiscence.
In the laboratory, the strength of this interaction can be measured by finding the melting temperature Tm necessary to break half of the hydrogen bonds. When all the base pairs in a DNA double helix melt, the strands separate and exist in solution as two entirely independent molecules. These single-stranded DNA molecules have no single common shape, but some conformations are more stable than others.
Sources: en.wikipedia.org
== Protein == Seryl-tRNA synthetase is made up of 514 amino acid residues as weighs 58,777 Da. It exists as a homodimer of two identical subunits, with the tRNA molecule binding across the dimer by similarity. It has two distinct domains:
Abdomen and obliques (belly) Crunch (i) Leg raise (c) Russian twist (c) Sit-up (c) Biceps (front of upper arms) Biceps curl (i) Pull ups with a supinated grip Calves Calf raise (i) Deltoids (shoulders) Front raise (i) Head stand into Handstand push-up (c) Lateral raise (i) Military press (c) Rear delt raise (i) Shoulder press (c) Upright row (c) Forearms Wrist curl (i) Wrist extension (i) Hamstrings (back of thighs) Deadlift (c) Frog jumping (i) Good-morning (exercise) (c) Leg curl (i) Squat (c) Lats and trapezius (back) Bent-over row (c) Chin-up (c) Pulldown (c) Pullup (c) Seated row (c) Shoulder shrug (i) Supine row (c) Lower back Deadlift (c) Good-morning (exercise) (c) Hyperextension (c) Pectorals (chest) Bench press (c) Chest fly (i) Dips (c) Machine fly (i) Push-up (c) Pelvis Vaginal weightlifting Quadriceps (front of thighs) Frog Jumping (i) Leg extension (i) Leg press (c) Lunge (c) Squat (c) Triceps (back of upper arms) Close-grip bench press (c) Dips (c) Push-down (exercise) (i) Lying triceps extensions (i)
=== General xenarthran research === McDonald et al. (2026) study the composition of the xenarthran assemblage from the Sistema Calera Cave (Mexico), reporting evidence of presence of Glyptotherium cylindricum and three sloth taxa, and report that the studied site represents the second known locality preserving fossil material of both Eremotherium and Nothrotheriops.
== Manual therapy == Range of motion (ROM) activities are beneficial for increasing joint mobility, reducing hypomobility. ROM activities can include stretching and staying active. Impertinent factors, including intensity, duration, and frequency, can affect how well stretching can aid in reducing hypomobility. Intensity is defined as the joint interaction with the amount of force during an exercise. During ROM exercises, intensity needs to be a consistent substantial force. A lack of force during exercises won't improve hypomobility. Duration and frequency, pertaining to time, is important when pertaining to exercise skills. Increasing the duration or frequency of a ROM exercise will produce more results. When heat is introduced into manual therapy, joints are more relaxed. This allows the joints to react more to the exercises performed, such as stretching. Some heating methods include just warming up before performing any exercises. This can include subtle motions or movements of the joints. Using actual heat can warm up and relax any tightness in the joints. Muscles are able to be manipulated easier, which increases effectiveness of manual therapy.
== Control and detection == The use of bracken fern as human food is mainly a historical question. The rhizomes of these plants served as human food in Scotland during the First World War. In America (USA, Canada), Russia, China and Japan, fern is grown commercially for human use. The usual procedure that is performed before eating the plant is to pre-treat the fern with boiling water in the presence of different chemicals, such as sodium bicarbonate and wood ash, to degrade or inactivate ptaquiloside and other toxic agents. Nevertheless, some carcinogenic activity persists even after the treatment. As shown by Kamon and Hirayama, the risk of oesophageal cancer was increased approximately by 2.1 in men and 3.7 in women who regularly consume bracken in Japan. Recent researches have suggested that sulfur-containing amino acids can potentially be used under appropriate conditions as detoxifying agents for ptaquiloside and selenium supplementation can prevent as well as reverse the immunotoxic effects induced by ptaquiloside. Ptaquiloside in the aqueous extract of bracken can be detected using different instrumental methods: thin-layer chromatography–densitometry (TLC-densitometry), high-performance liquid chromatography (HPLC), gas chromatography–mass spectrometry (GCMS), and liquid chromatography–mass spectrometry (LC-MS).
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.